Dov Elefant's most recent trade in Femasys Inc was a trade of 19,608 Common Stock done at an average price of $1.0 . Disclosure was reported to the exchange on June 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Femasys Inc | Dov Elefant | Chief Financial Officer | 02 Jun 2025 | 19,608 | 19,608 | - | 1.0 | 20,000 | Common Stock | |
| Femasys Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 114,300 | 114,300 | - | - | Stock Option (Right to Buy) | |
| Femasys Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 72,045 | 72,045 | - | - | Stock Option (Right to Buy) | |
| Femasys Inc | Elefant Dov | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2024 | 84,000 | 84,000 | - | - | Stock Option (Right to Buy) | |
| Femasys Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 204,700 | 204,700 | - | - | Stock Option (Right to Buy) | |
| Femasys Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 105,200 | 105,200 | - | - | Stock Option (Right to Buy) | |
| Femasys Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Cellectar Biosciences Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2022 | 422,000 | 422,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Dov Elefant | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2021 | 430,000 | 430,000 | - | - | Stock option (right to buy) | |
| Cellectar Biosciences Inc | Dov Elefant | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.35 per share. | 28 Dec 2020 | 7,407 | 11,755 (0%) | 0% | 1.3 | 9,999 | Common Stock |